BACKGROUND: Sensitivity to glucocorticoids may be related to the concentration of glucocorticoid receptors alpha (GRalpha) and beta (GRbeta). A study was undertaken to assess GRalpha and GRbeta expression in steroid insensitive interstitial lung disease (idiopathic pulmonary fibrosis (IPF)) and steroid sensitive interstitial lung diseases (sarcoidosis and cryptogenic organising pneumonia (COP)). METHODS: Lung tissue was obtained from control subjects and from patients with IPF, sarcoidosis, and COP. Pulmonary function tests were carried out at the time of lung biopsy and every 3 months. GRalpha and GRbeta expression was evaluated by both competitive RT-PCR and immunohistochemistry. Data are presented as median and 25-75th percentile. RESULTS: GRalpha mRNA expression (10(5) cDNA copies/ micro g total RNA) was higher in patients with steroid sensitive interstitial lung diseases (10.0; 7.8-14.9; n = 11) than in patients with IPF (4.4; 3.2-6.6; n = 19; p<0.001). GRbeta expression was at least 1000 times lower than that of GRalpha and did not differ between the three groups. A negative correlation was found between GRalpha mRNA levels and the fibrotic pathology score of the tissue (r = -0.484, p<0.01) and a positive correlation was found between GRalpha mRNA levels and improvement in forced vital capacity (r = 0.633; p<0.01) after treatment of patients with glucocorticoids. Immunoreactivity for GR protein was also higher in patients with sarcoidosis and COP than in those with IPF. CONCLUSION: The variable response of some interstitial lung diseases to steroid treatment may be the result of differences in the expression of GRalpha.
BACKGROUND: Sensitivity to glucocorticoids may be related to the concentration of glucocorticoid receptors alpha (GRalpha) and beta (GRbeta). A study was undertaken to assess GRalpha and GRbeta expression in steroid insensitive interstitial lung disease (idiopathic pulmonary fibrosis (IPF)) and steroid sensitive interstitial lung diseases (sarcoidosis and cryptogenic organising pneumonia (COP)). METHODS: Lung tissue was obtained from control subjects and from patients with IPF, sarcoidosis, and COP. Pulmonary function tests were carried out at the time of lung biopsy and every 3 months. GRalpha and GRbeta expression was evaluated by both competitive RT-PCR and immunohistochemistry. Data are presented as median and 25-75th percentile. RESULTS: GRalpha mRNA expression (10(5) cDNA copies/ micro g total RNA) was higher in patients with steroid sensitive interstitial lung diseases (10.0; 7.8-14.9; n = 11) than in patients with IPF (4.4; 3.2-6.6; n = 19; p<0.001). GRbeta expression was at least 1000 times lower than that of GRalpha and did not differ between the three groups. A negative correlation was found between GRalpha mRNA levels and the fibrotic pathology score of the tissue (r = -0.484, p<0.01) and a positive correlation was found between GRalpha mRNA levels and improvement in forced vital capacity (r = 0.633; p<0.01) after treatment of patients with glucocorticoids. Immunoreactivity for GR protein was also higher in patients with sarcoidosis and COP than in those with IPF. CONCLUSION: The variable response of some interstitial lung diseases to steroid treatment may be the result of differences in the expression of GRalpha.
Authors: R Lazor; A Vandevenne; A Pelletier; P Leclerc; I Court-Fortune; J F Cordier Journal: Am J Respir Crit Care Med Date: 2000-08 Impact factor: 21.405
Authors: D L Hamilos; D Y Leung; S Muro; A M Kahn; S S Hamilos; S E Thawley; Q A Hamid Journal: J Allergy Clin Immunol Date: 2001-07 Impact factor: 10.793
Authors: L Pujols; J Mullol; M Pérez; J Roca-Ferrer; M Juan; A Xaubet; J A Cidlowski; C Picado Journal: Am J Respir Cell Mol Biol Date: 2001-01 Impact factor: 6.914
Authors: K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez Journal: Am J Med Date: 2001-03 Impact factor: 4.965
Authors: A Angeli; A Dovio; M L Sartori; R G Masera; B Ceoloni; P Prolo; S Racca; F Chiappelli Journal: Ann N Y Acad Sci Date: 2002-06 Impact factor: 5.691
Authors: Elena Goleva; Ling-Bo Li; P Taylor Eves; Matthew J Strand; Richard J Martin; Donald Y M Leung Journal: Am J Respir Crit Care Med Date: 2005-12-30 Impact factor: 21.405
Authors: P Trebble; L Matthews; J Blaikley; A W O Wayte; G C M Black; A Wilton; D W Ray Journal: J Clin Endocrinol Metab Date: 2010-09-22 Impact factor: 5.958
Authors: Erica L T van den Akker; Jan W Koper; Koen Joosten; Frank H de Jong; Jan A Hazelzet; Steven W J Lamberts; Anita C S Hokken-Koelega Journal: Intensive Care Med Date: 2009-04-17 Impact factor: 17.440